ACT's Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access Journal
Source: ACT's Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access Journal - MarketWatch
Quality Peer-Reviewed Journal from Mary Ann Liebert Publishers Provides Forum for Broad Spectrum of Scientific Topics Based on Innovative Open Access Model
MARLBOROUGH, Mass., Feb 11, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the regenerative medicine space, announced today that the Company's chief scientific officer, Robert Lanza, MD, has been appointed editor-in-chief of the scientific journal BioResearch Open Access. The publication's current editor, Jane Taylor, Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, will continue in her role as Editor.
BioResearch Open Access, in its second year of publication, is a quality peer-reviewed open access journal for the rapid-publication of a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. The Journal welcomes basic science and translational research in the form of original research articles, comprehensive review articles, mini-reviews, rapid communications, brief reports, technical reports, hypothesis articles, perspectives, and letters to the editor. All articles in BioResearch Open Access are rapidly reviewed and published online within 4 weeks of acceptance at BioResearch Open Access . Articles are fully open access and posted on the National Institutes of Health's (NIH) PubMedCentral. BioResearch Open Access is fully NIH-, HHMI-, and Wellcome Trust-compliant.
"BioResearch Open Access is a fully-refereed multidisciplinary journal and provides all the checks and balances that rigorous peer review ensures," said Mary Ann Liebert, president of Mary Ann Liebert, Inc., publishers. "An outstanding editorial team comprised of experienced journal editors guarantees the integrity of the Journal, and we are very pleased to fortify it with the appointment of Dr. Lanza."
According to the European Science Foundation's Science Policy Briefing (September 2012), "Open access publishing has the potential to revolutionise the way in which biomedical scientists publish and access the latest results in their field."